ArticleACS applied materials & interfaces2026
Multifunctional Selenium-Sulfur-Doped Carbon Dots Nanozymes with Thioredoxin Reductase Activity for Regenerative Therapy of Infected Wounds.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial-infected wounds exhibit delayed healing due to numerous pathological factors, including excessive inflammatory responses, reactive oxygen species (ROS) accumulation, and impaired angiogenesis. Current clinical therapies predominantly employ antimicrobial monotherapy, failing to address the complex interplay among the other pathogenic factors. Herein, we synthesized multifunctional selenium-sulfur-doped carbon dots (SE/S-CDs) nanozymes using selenocystine and cysteine as precursors to simultaneously target multiple pathological hallmarks of infected wounds. Primarily, SE/S-CDs exerted potent antibacterial activity by compromising the integrity of bacterial cell membranes, thereby achieving robust pathogen clearance in infected wounds. Furthermore, owing to the presence of Se-S dynamic bonds, they can specifically activate the thioredoxin reductase (TrxR) pathway, efficiently scavenging ROS and alleviating the inflammatory response. In addition, SE/S-CDs upregulated the hypoxia-inducible factor 1α (HIF-1α) signaling pathway, promoting the expression of proangiogenic genes and accelerating neovascularization and tissue repair. Collectively, SE/S-CDs modulated the infected wound microenvironment through a coordinated "antibacterial-anti-inflammatory-antioxidant-proangiogenic" cascade, demonstrating excellent, integrated therapeutic outcomes. This integrated therapeutic strategy not only exhibits efficacy in infected wound treatment but also holds translational potential for other infection-related and oxidative stress-driven diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.